Sign up here for our daily coronovirus newsletter that you need to know, and Subscribe to our Kovid-19 podcast for the latest news and analysis.
The latest Kovid-19 vaccine candidate is the first to begin human trials where volunteers will not receive a painful injection. Instead, they will receive a spray through the nose.
China approved on Wednesday Human testing for the Phase I nasal spray vaccine, co-developed by researchers at the University of Zima and the University of Hong Kong, as well as by the vaccine manufacturer Beijing Wantai Biological Pharmacy Enterprise Co.
Intranasal spray has been developed as the first one The vaccine for the flu is recommended for use among children and adults who wish to avoid more common needle injections. While it is not the most frequent option for childbirth, scientists around the world are working to develop sprays as an alternative to muscle jabs for all types of vaccines.
Candidate of china
Intranasal vaccine is 10th candidate from China to advance to the critical stage of human testing. The country is making its lead in vaccine development after the Western Front AstraZeneca plc had to Stop your last stage human test to check for spinal cord disease in a person receiving an experimental shot.
Intranasal sprays contain a weak flu virus that carries genetic segments of the spike protein of the coronovirus. Administered via the Nashik route, it mimics the natural infection of respiratory viruses, which stimulate the body’s immune response against the pathogen that causes Kovid-19, according to Science and Technology Daily, China A paper affiliated with the Ministry of Science and Technology.
Some scientists hope A vaccine that is secreted through the nose may have a better chance of preventing the spread of insidious virus through the respiratory tract. A needle injection can cause a systemic immune response to prevent severe disease, but may not be strong enough to ward off infection.
Preclinical studies have shown that nasal vaccines can significantly reduce lung damage between mice and hamsters due to the challenge posed by coralviruses, Science and Technology Daily.
Nasal spray Currently about 35 other candidates in human trials, as the first global race with an effective vaccine against the deadly pathogen. In view of AstraZeneca’s setback, including China’s most advanced vaccine developers, CanSino Biologics Inc. And state owned The China National Biotech Group Company has emphasized the safety of its own shots.
CNBG said that the two shots it is testing are effective in preventing infection. An article published in Science and Technology Daily stated that none of the Chinese diplomats and activists had seen the virus, which many months after receiving the vaccine, Zhou Song, CNBG general counsel, reported the infection abroad. Give.
CanSino, which uses a vaccine-making technology similar to AstraZeneca, said its military-backed shot is safe and the test did not have any serious side effects.
Can Taano co-founder and chief scientific officer Zhu Tao defended the vaccine against criticism that it appears to trigger fewer antibodies than those generated by rivals, including AstraZeneca and rivals. Modern inc. The variation in antibody readings is a result of using different measuring methods, Zhu said in a presentation to investors this week.
– Assisted by Sharon Chen and Dong Luu